Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published– Case Report Details 21 Months of ...
Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...
Pediatrix Medical Group, Inc. (NYSE: MD) will host an investor conference call and webcast on Thursday, October 29, 2026 at 9:00 a.m. ET to discuss results from operations for the quarter ended ...
Two Decades of Progress, a New Future for Pediatric AML / Acute Lymphoblastic Leukemia, Acute promyelocytic Leukemia, ALL, ...
The researchers evaluated real-world data detailing treatment patterns among 10,313 patients with GPP. Baseline demographics ...
A retrospective study at Great Ormond Street Hospital finds the PIM-3 score matches or exceeds SNAPPE II and SNAP II in ...
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...
Roche and Teva gained FDA approvals, while Mesa Laboratories and GSK moved ahead with workforce cuts. Strategic moves also took center stage, with Labcorp, AstraZeneca, Galderma and Zealand Pharma ...
Rapid genome sequencing has proven itself in the ICU. Data from the first known study in neuro-specific pediatric inpatients suggest it may be just as valuable on the general pediatric floor.
A British poll revives debate over autism and ADHD diagnoses. How U.S., U.K. and European statistics, diagnostic standards and treatment options compare.
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Health Canada has issued ...
AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results